Endurance training increases exercise-induced prostacyclin release in young, healthy men - Relationship with VO2max

Pharmacological Reports

Volumn 62, Issue 3, 2010, Pages 494-502

  Zoladz, Jerzy A ^a   Majerczak, Joanna ^a   Duda, Krzysztof ^a   Chłopicki, Stefan ^b  

^a UNIVERSITY OF PHYSICAL EDUCATION   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Endurance training; Exercise; Maximal oxygen uptake; Power output; Prostacyclin

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; PROSTACYCLIN;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; ENDURANCE TRAINING; EXERCISE; EXERCISE INTENSITY; EXHAUSTION; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMAL OXYGEN UPTAKE; NORMAL HUMAN; OXYGEN CONSUMPTION; PROSTAGLANDIN BLOOD LEVEL; VENOUS BLOOD; BLOOD; ENDURANCE; EXERCISE TEST; LUNG VENTILATION; METABOLISM; PHYSIOLOGY; REST; YOUNG ADULT;

6-KETOPROSTAGLANDIN F1 ALPHA; EPOPROSTENOL; EXERCISE; EXERCISE TEST; HUMANS; MALE; OXYGEN CONSUMPTION; PHYSICAL ENDURANCE; PULMONARY VENTILATION; REST; YOUNG ADULT;

EID: 77954851317     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70305-4     Document Type: Article

References (54)

1. Aird WC: Endothelium in health and disease. Pharmacol Rep, 2008, 60, 139-143.
2. Andersen P, Saltin B: Maximal perfusion of skeletal muscle in man. J Physiol, 1985, 366, 233-249.
3. Barrow SE, Dollery CT, Heavey DJ, Hickling NE, Ritter JM, Vial J: Effect of vasoactive peptides on prostacyclin synthesis in man. Br J Pharmacol, 1986, 87, 243-247.
4. Barstow TJ, Jones AM, Nguyen PH, Casaburi R: Influence of muscle fiber type and pedal frequency on oxygen uptake kinetics of heavy exercise. J Appl Physiol, 1996, 81, 1642-1650.
5. Bartsch P: Platelet activation with exercise and risk of cardiac events. Lancet, 1999, 354, 1747-1748.
6. Bassett DT, Holewy ET: Limiting factors for maximum oxygen uptake and determinants of endurance performance. Med Sci Sports Exerc, 2000, 32, 70-84.
7. Blumberg FC, Riegger GA, Pfeifer M: Hemodynamic effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise. Chest, 2002, 121, 1566-1571.
8. Boger RH, Bode-Boger SM, Schroder EP, Tsikas D, Frolich JC: Increased prostacyclin production during exercise in untrained and trained men: effect of low-dose aspirin. J Appl Physiol, 1995, 78, 1832-1838.
9. Bouchard C, Rankinen T: Individual differences in response to regular physical activity. Med Sci Sports Exerc, 2001, 33, Suppl 6, S446-S451.
10. Bugiardini R, Galvani M, Ferrini D, Gridelli C, Mari L, Puddu P, Lenzi S: Effects of iloprost, a stable prostacyclin analog, on exercise capacity and platelet aggregation in stable angina pectoris. Am J Cardiol, 1986, 58, 453-459.
11. Chłopicki S, Gryglewski RJ: Angiotensin converting enzyme (ACE) and HydroxyMethylGlutaryl-CoA (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium. Pharmacol Rep, 2005, 57, Suppl, 86-96.
12. Ciuffetti G, Sokola E, Lombardini R, Pasqualini L, Pirro M, Mannarino E: The influence of iloprost on blood rheology and tissue perfusion in patients with intermittent claudication. Kardiol Pol, 2003, 59, 197-204.
13. 2max, and response to endurance training. Med Sci Sports Exerc, 1993, 25, 766-774.
14. Frandsen U, Bangsbo J, Langberg H, Saltin B, Hellsten Y: Inhibition of nitric oxide synthesis by systemic NG-monomethyl-L-arginine administration in humans: effects on interstitial adenosine, prostacyclin and potassium concentrations in resting and contracting skeletal muscle. J Vasc Res, 2000, 37, 297-302.
15. Fukuoka Y, Grassi B, Conti M, Guiducci D, Sutti M, Marconi C, Cerretelli P: Early effects of exercise training on onand off-kinetics in 50-year-old subjects. Pflugers Arch, 2002, 443, 690-697.
16. Green DJ, Maiorana A, O'driscoll G, Taylor R: Effect of exercise training on endotheliumderived nitric oxide function in humans. J Physiol, 2004, 561, 1-25.
17. Grosser T, Fries S, Fitzgerald GA: Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest, 2006,116,4-15.
18. Gryglewski RJ: Prostacyclin among prostanoids. Pharmacol Rep, 2008, 60, 3-11.
19. Gryglewski RJ: Prostaglandins, platelets, and atherosclerosis. CRC Crit Rev Biochem, 1980, 7, 291-338.
20. Hill LL, Pearl RG: Combined inhaled nitric oxide and inhaled prostacyclin during experimental chronic pulmonary hypertension. J Appl Physiol, 1999, 86, 1160-1164.
21. Humbert M, Sitbon O, Simonneau G: Treatment of pulmonary arterial hypertension. (Review). N Engl J Med, 2004,351,1425-1436.
22. 2) and thromboxane A2 (TXA2) levels during incremental dynamic exercise in humans determined by in vivo microdialysis. Prostaglandins Leukot Essent Fatty Acids, 2001, 64, 259-263.
23. Kerbaul F, Brimioulle S, Rondelet B, Dewachter C, Hubloue I, Naeije R: How prostacyclin improves cardiac output in right heart failure in conjunction with pulmonary hypertension. Am J Respir Crit Care Med, 2007, 175, 846-850.
24. Kestin AS, Ellis PA, Barnard MR, Errichetti A, Rosner BA, Michelson AD: Effect of strenuous exercise on platelet activation state and reactivity. Circulation, 1993, 88,1502-1511.
25. Koivisto VA, Jantunen M, Sane T, Helve E, Pelkonen R, Viinikka L, Ylikorkala O: Stimulation of prostacyclin synthesis by physical exercise in type I diabetes. Diabetes Care, 1989, 12, 609-614.
26. Kojda G, Hambrecht R: Molecular mechanisms of vascular adaptations to exercise. Physical activity as an effective antioxidant therapy? Cardiovasc Res, 2005, 67, 187-197.
27. Li N, He S, Blomback M, Hjemdahl P: Platelet activity, coagulation, and fibrinolysis during exercise in healthy males: effects of thrombin inhibition by argatroban and enoxaparin. Arterioscler Thromb Vasc Biol, 2007, 27, 407-413.
28. Mehta J, Mehta P, Horalek C: The significance of platelet-vessel wall prostaglandin equilibrium during exercise-induced stress. Am Heart J, 1983, 105, 895-900.
29. Merkus D, Sorop O, Houweling B, Boomsma F, Van Den Meiracker AH, Duncker DJ: NO and prostanoids blunt endothelin-mediated coronary vasoconstrictor influence in exercising swine. Am J Physiol Heart Circ Physiol, 2006, 291, H2075-H2081.
30. 2)-mimetics in severe peripheral vascular disease. Biomed Biochim Acta, 1988, 47, S40-S44.
31. Nosaka S, Hashimoto M, Sasaki T, Ku K, Saitoh Y, Ya-mauchi M, Tanabe Y et al.: The effects of transmural pressure on prostacyclin release from porcine endocardial endothelial cellscomparison with vascular endothelial cells. Pflugers Arch, 1997, 433, 848-850.
32. Pasqualini L, Pirro M, Lombardini R, Ciuffetti G, Dra-gani P, Mannarino E: A human model of plateletleucocyte adhesive interactions during controlled ischaemia in patients with peripheral vascular disease. J Clin Pathol, 2002, 55, 946-950.
33. Petidis K, Douma S, Doumas M, Basagiannis I, Vogi-atzis K, Zamboulis C: The interaction of vasoactive substances during exercise modulates platelet aggregation in hypertension and coronary artery disease. BMC Cardiovasc Disord, 2008, 8, 11.
34. Prud'homme D, Bouchard C, Leblanc C, Landry F, Fontaine E: Sensitivity of maximal aerobic power to training is genotype-dependent. Med Sci Sports Exerc, 1984, 16, 489-493.
35. Raczka E, Quintana A: Effects of intravenous administration of prostacyclin on regional blood circulation in awake rats. Br J Pharmacol, 1999, 126, 1325-1332.
36. Rasmanis G, Vesterqvist O, Green K, Edhag O, Henriksson P: Prostacyclin production in myocardial infarction in the acute phase and during follow-up. J Intern Med, 1991,229,135-141.
37. Richardson RS, Saltin B: Human muscle blood flow and metabolism studied in the isolated quadriceps muscles. Med Sci Sports Exerc, 1998, 30, 28-33.
38. Ritter JM, Barrow SE, Blair IA, Dollery CT: Release of prostacyclin in vivo and its role in man. Lancet, 1983, 1, 317-319.
39. Rocca GD, Coccia C, Pompei L, Ruberto F, Venuta F, De Giacomo T, Pietropaoli P: Hemodynamic and oxygenation changes of combined therapy with inhaled nitric oxide and inhaled aerosolized prostacyclin. J Cardiothorac Vasc Anesth, 2001, 15, 224-227.
40. Sakuma T, Zhao Y, Sugita M, Sagawa M, Hida M, Toga H: A prostacyclin analogue, OP-41483a-CD, restores the ability of a β2-adrenergic agonist to stimulate alveolar fluid clearance in rats. Surg Today, 2004, 34, 429-436.
41. Saltin B, Calbet JA: Point: in health and in a normoxic environment, VO2 max is limited primarily by cardiac output and locomotor muscle blood flow. J Appl Physiol, 2006, 100, 744-745.
42. Sargeant AJ: Neuromuscular determinants of human performance. In: The Physiological determinants of exercise tolerance in humans. Eds. Sargeant AJ, Whipp BJ, Portland Press, London, 1999, 13-28.
43. Stergioulas AT, Filippou DK: Effects of physical conditioning on lipids and arachidonic acid metabolites in untrained boys: a longitudinal study. Appl Physiol Nutr Metab, 2006, 31,432-441.
44. Tabet JY, Tabet JY, Meurin P, Beauvais F, Weber H, Renaud N, Thabut G et al.: Absence of exercise capacity improvement after exercise training program: a strong prognostic factor in patients with chronic heart failure. Circ Heart Fail, 2008, 1, 220-226.
45. Vanhoutte PM: Ageing and endothelial dysfunction. Eur Heart J, 2002, 4, A8-A17.
46. Wax D, Garofano R, Barst RJ: Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension. Chest, 1999, 116, 914-920.
47. Wennmalm A, Nowak J, Bjuro T: Excretion of thromboxane A2 and prostacyclin metabolites before and after exercise testing in patients with and without signs of ischemic heart disease. Circulation, 1990, 82, 1737-1743.
48. Wensel R, Opitz CF, Ewert R, Bruch L, Kleber FX: Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension. Circulation, 2000, 101, 2388-2392.
49. Whipp BJ: Domains of aerobic function and their limiting parameters. In: The Physiology and Pathophysiology of Exercise Tolerance. Eds. Steinacker JM, Ward SA, Plenum Press, New York, 1996, 83-89.
50. Womack CJ, Davis SE, Blumer JL, Barrett E, Weltman AL, Gaesser GA: Slow component of O2 uptake during heavy exercise: adaptation to endurance training. J Appl Physiol, 1995, 79, 838-845.
51. Woodman CR, Thompson MA, Turk JR, Laughlin MH: Endurance exercise training improves endotheliumdependent relaxation in brachial arteries from hypercholesterolemic male pigs. J Appl Physiol, 2005, 99, 1412-1421.
52. Zoladz JA, Duda K, Majerczak J: Oxygen uptake does not increase linearly at high power outputs during incremental exercise test in humans. Eur J Appl Physiol, 1998,77,445-451.
53. 2max in young healthy men. Physiol Res, 2009, 58, 229-238.
54. Zoladz JA, Rademaker ACHJ, Sargeant AJ: Non-linear relationship between O2 uptake and power output at high intensities of exercise in humans. J Physiol, 1995, 488, 211-217.